Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13977964 | 0.83 | AURKA (0.59) | AURKAGRM2KDM4EKMT2AALOX15 | |
| SCHEMBL3333164 | 0.83 | GRM2 (0.48) | AURKAGRM2KDM4EKMT2AALOX15 | |
| SCHEMBL2222480 | 0.82 | ADORA2A (0.47) | AURKAGRM2KDM4EKMT2AADORA2A | |
| SCHEMBL8114876 | 0.81 | GPR35 (0.54) | AURKAGRM2KDM4EKMT2AALOX15 | |
| SCHEMBL30744879 | 0.81 | KDM4E (0.51) | AURKAGRM2KDM4EKMT2AALOX15 | |
| SCHEMBL30421043 | 0.78 | ALOX15 (0.62) | AURKAGRM2KDM4EALOX15IGFBP3 | |
| SCHEMBL30744928 | 0.77 | GRM2 (0.43) | AURKAGRM2KDM4EALOX15IGFBP3 | |
| SCHEMBL14919681 | 0.77 | GRM2 (0.78) | AURKAGRM2IGFBP3 | |
| SCHEMBL837668 | 0.75 | ALOX15 (0.58) | GRM2KDM4EKMT2AALOX15MEN1 | |
| SCHEMBL4751890 | 0.75 | KDM4E (0.66) | KDM4EKMT2AALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709621-B1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2709621-B1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8940765-B2 | N-linked quinolineamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940765-B2 | N-linked quinolineamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940765-B2 | N-linked quinolineamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140200222-A1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140200222-A1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| EP-2709621-A1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158474-A1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158474-A1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200222-A1 | N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | AURKA 2964/4885GRM2 95/4885KDM4E 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.